本文已被:浏览 253次 下载 175次
投稿时间:2025-11-19 网络发布日期:2026-08-25
投稿时间:2025-11-19 网络发布日期:2026-08-25
中文摘要: 表皮生长因子受体(EGFR)突变是晚期非小细胞肺癌(NSCLC)最常见的驱动基因改变。尽管EGFR-酪氨酸激酶抑制剂(TKI)显著改善了患者预后,但获得性耐药仍是临床亟待解决的难题。虽然免疫检查点抑制剂改变了驱动基因阴性的晚期NSCLC的治疗格局,但其在EGFR突变患者一线治疗中的获益有限。鉴于EGFR-TKI 对肿瘤微环境的潜在重塑作用及相关临床证据的积累,免疫联合治疗有望成为克服耐药的新策略。本文综述了EGFR-TKI耐药后免疫治疗的理论基础、临床现状及优势人群探索,旨在为该类患者的精准治疗提供决策依据。
Abstract:Epidermal growth factor receptor(EGFR)mutations are the most common driver alterations in advanced non-small cell lung cancer(NSCLC). Although EGFR-tyrosine kinase inhibitors(TKI)have significantly improved patient prognosis,the development of acquired resistance remains a critical challenge in clinical practice. While immune checkpoint inhibitors have revolutionized the treatment landscape for driver gene-negative advanced NSCLC,their efficacy as first-line therapy in EGFR-mutant patients is limited.However,given the potential of EGFR-TKI to remodel the tumor microenvironment and the accumulation of relevant clinical evidence,immune combination therapy is emerging as a promising strategy to overcome resistance. This review summarizes the theoretical basis,clinical status,and exploration of potential beneficiary populations for immunotherapy following EGFR-TKI resistance,aiming to provide a foundation for precise treatment decision-making in these patients.
keywords: Non-small cell lung cancer Epidermal growth factor receptor Acquired resistance Immunotherapy Biomarker Tyrosine kinase inhibitor Tumor microenvironment Immune checkpoint inhibitor
文章编号: 中图分类号:R734.2 R453 文献标志码:A
基金项目:南京市卫生科技发展专项资金(GAX22280);恒学—肿瘤学科科研能力支持提升项目(HJ-HX-ZLXD-202209-003)
附件
| Author Name | Affiliation |
| MU Hanshuo,HAN Yu,ZHANG Yu | Department of Respiratory Medicine,Nanjing Chest Hospital,the Brain Hospital Affiliated to Nanjing Medical University,Nanjing,Jiangsu 210029,China |
引用文本:
慕函朔, 韩玉, 张宇.表皮生长因子受体突变晚期非小细胞肺癌靶向治疗耐药后的免疫联合治疗[J].中国临床研究,2026,39(8):1295-1300.
慕函朔, 韩玉, 张宇.表皮生长因子受体突变晚期非小细胞肺癌靶向治疗耐药后的免疫联合治疗[J].中国临床研究,2026,39(8):1295-1300.
